肝细胞癌患者肿瘤相关抗原免疫应答特征及免疫细胞谱分析
本研究分析了32例HBV相关、42例HCV相关和18例NASH相关肝细胞癌患者对肿瘤相关抗原(TAA)特异性T细胞的免疫应答及免疫细胞谱。三组间免疫应答和免疫细胞谱明显不同,NASH相关HCC组TAA免疫应答较弱,且eTreg和CTLA-4+CD8+T细胞频率高;抗CTLA-4抗体可恢复TAA特异性T细胞应答。
要点
- NASH相关HCC组TAA特异性T细胞免疫应答弱于HBV和HCV相关HCC组。
- NASH相关HCC组效应性调节性T细胞和强表达CTLA-4的CD8+T细胞频率高。
- CXCR3+ eTreg和CTLA-4+CD8+T细胞频率与TAA特异性T细胞应答强度呈负相关。
核心结论
- 三组HCC患者对TAA的免疫应答明显不同,且与免疫细胞谱相关,提示基于病因开发免疫治疗可能带来更有效的治疗结局。
研究设计与样本
- 研究纳入32例HBV相关HCC、42例HCV相关HCC和18例NASH相关HCC患者,检测TAA特异性T细胞频率、免疫细胞表面标志物表达及HCC组织中各TAA表达。
主要发现
- NASH相关HCC组TAA免疫应答弱于HBV相关和HCV相关HCC组。
- NASH相关HCC组效应性调节性T细胞(eTreg)和强表达CTLA-4的CD8+T细胞频率高。
- HBV相关HCC组强表达PD-1的CD8+T细胞频率最高。
- CXCR3+ eTreg和CTLA-4+CD8+T细胞频率与TAA特异性T细胞免疫应答强度呈负相关。
- 抗CTLA-4抗体可恢复TAA特异性T细胞应答。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Host antitumor immune responses may be different between hepatocellular carcinoma (HCC) caused by metabolic disorders and HCC associated with hepatitis virus infection. In this study, we examined the immune response of tumor-associated antigen (TAA)-specific T cells and immune cell profile in patients with HCC separated by cause. Thirty-two patients with hepatitis B virus (HBV)-related HCC, 42 patients with hepatitis C virus-related HCC, and 18 patients with nonalcoholic steatohepatitis (NASH)-related HCC were analyzed. The frequencies of TAA-specific T cells, the expression levels of surface markers on each immune cell, and the expression of each TAA in HCC tissue were measured. The immune response to TAA and immune cell profile were markedly different among the three groups. The immune response to TAA in the NASH-related HCC group was weaker than the responses in the other two groups. In patients with NASH-related HCC, the frequencies of effector regulatory T cells (eTregs) and cluster of differentiation 8-positive (CD8+ ) T cells strongly expressing cytotoxic T-lymphocyte antigen (CTLA)-4 were high. The frequency of CD8+ T cells strongly expressing programmed cell death 1 was the highest in patients with HBV-related HCC. Among these immune cell profiles, the frequencies of C-X-C motif chemokine receptor 3+ eTregs and CTLA-4+ CD8+ T cells were inversely correlated with the strength of the TAA-specific T-cell immune response, and the restoration of TAA-specific T-cell responses by anti-CTLA-4 antibody was observed. Conclusion: The immune response to TAA were markedly different among the three groups, and a correlation with the immune cell profile was observed, suggesting that development of immunotherapy based on the etiology of HCC may lead to more effective treatment outcomes.
引用
- Inada Y, Mizukoshi E, Seike T, et al. Characteristics of Immune Response to Tumor-Associated Antigens and Immune Cell Profile in Patients With Hepatocellular Carcinoma. Hepatology. 2018. PMID: 30102778. doi:10.1002/hep.30212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。